GF
RVNC

Gabelli Funds’s Revance Therapeutics, Inc. RVNC Stock Holding History

Gabelli Funds’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,262,487
Closed -$3.84M – 1132
2024
Q4 		$3.84M Buy
1,262,487
+171,323
+16% +$746K 0.03% 516
2024
Q3 		$5.66M Buy
+1,091,164
New +$5.42M 0.04% 432

Other funds holding RVNC

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Gabelli Funds's RVNC Position: Q1 2025 in Review

Gabelli Funds sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2025, closing a stake of 1,262,487 shares — an estimated $3.84M sold.

Gabelli Funds first reported a position in RVNC in Q3 2024 and held it in 2 quarters. The position peaked at $5.66M in Q3 2024. 1 fund tracked by Wall St. Rank holds RVNC as of Q1 2025.

  • Gabelli Funds reported no remaining Revance Therapeutics, Inc. position as of Q1 2025 after selling out during the quarter.
  • Gabelli Funds sold 1,262,487 Revance Therapeutics, Inc. shares in Q1 2025, an estimated $3.84M.
  • Gabelli Funds first reported a position in Revance Therapeutics, Inc. in Q3 2024 and held it in 2 quarters.
  • Gabelli Funds's Revance Therapeutics, Inc. position peaked at $5.66M in Q3 2024.
  • 1 fund tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2025.

Based on Gabelli Funds's 13F filing for Q1 2025, filed 14 May 2025.